Oak Associates Ltd. OH Invests $7.99 Million in Bristol Myers Squibb Company $BMY

Oak Associates Ltd. OH bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the first quarter, Holdings Channel.com reports. The fund bought 131,790 shares of the biopharmaceutical company’s stock, valued at approximately $7,993,000.

A number of other large investors also recently bought and sold shares of the business. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at approximately $25,000. Physician Wealth Advisors Inc. raised its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the period. Bayban purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

BMY has been the subject of several recent analyst reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a report on Monday, July 6th. Guggenheim reiterated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Weiss Ratings lowered shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 16th. Bank of America lowered their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Finally, UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and an average target price of $61.25.

Bristol Myers Squibb Stock Up 1.3%

Shares of NYSE:BMY opened at $61.56 on Friday. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The stock has a market cap of $125.71 billion, a P/E ratio of 17.29, a PEG ratio of 0.17 and a beta of 0.23. The business has a fifty day moving average of $57.39 and a two-hundred day moving average of $58.00. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the previous year, the company posted $1.80 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is 70.79%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMY was highlighted as rising while the broader market dipped, suggesting investors were rotating into the name and viewing it as relatively resilient versus the market. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
• Positive Sentiment: Wall Street expectations point to earnings growth in next week’s report, and multiple articles framed Bristol Myers Squibb as having a strong chance to beat estimates, which can support the stock into the print. Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
• Positive Sentiment: An analyst-style momentum piece also described BMY as a top long-term momentum stock, reinforcing a constructive technical/relative-strength narrative. Why Bristol Myers Squibb (BMY) is a Top Momentum Stock for the Long-Term
• Neutral Sentiment: Bristol Myers Squibb is scheduled to report quarterly earnings next week, keeping the stock in a wait-and-see mode as investors look for confirmation of growth and guidance. Bristol Myers Squibb (BMY) to Release Quarterly Earnings on Thursday
• Neutral Sentiment: News that Alexandria Real Estate delivered a new Bristol Myers Squibb R&D hub in San Diego is operationally positive, but it is more of a long-term business development update than an immediate stock catalyst. Alexandria Real Estate Equities Delivers 427,000 RSF Bristol Myers Squibb R & D Hub
• Negative Sentiment: One MarketWatch item noted BMY underperformed peers despite daily gains, which suggests the move may be less impressive on a relative basis than it first appears. Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.